Darci Portie, NP
Family · Lake Charles, LANPI 1033592886
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,029 of the $62,607 with a category attached, or 78.3%. AbbVie accounts for 75.4% of it on its own, with 30 other manufacturers making up the rest. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $153.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$47K
- Pfizer$7K
- Biohaven Pharmaceuticals, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$877
- Novo Nordisk$670
- Lilly USA, LLC$526
- plus $4K from 25 others
What the payments were for
- Consulting fees$1,8753%
- Speaking & faculty fees$49,02978%
- Travel & lodging$1,0232%
- Food & beverage$10,51017%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 183 | $47,233 |
| Pfizer | 55 | $7,413 |
| Biohaven Pharmaceuticals, Inc. | 12 | $1,525 |
| Teva Pharmaceuticals USA, Inc. | 24 | $877 |
| Novo Nordisk | 11 | $670 |
| Lilly USA, LLC | 28 | $526 |
| AstraZeneca(2 entities) | 6 | $517 |
| Abbott | 5 | $380 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $340 |
| Amgen | 12 | $336 |
| Neurocrine Biosciences, Inc. | 4 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $237 |
| GSK | 2 | $223 |
| Otsuka America Pharmaceutical, Inc. | 2 | $221 |
| Lundbeck LLC | 12 | $199 |
| Astellas Pharma US Inc | 2 | $172 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $140 |
| Phathom Pharmaceuticals, Inc. | 1 | $127 |
| Boehringer Ingelheim | 2 | $126 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Upsher-smith Laboratories LLC | 8 | $124 |
| Dexcom, Inc. | 1 | $116 |
| Bayer | 1 | $114 |
| Jazz Pharmaceuticals Inc. | 1 | $111 |
| Gilead | 1 | $111 |
| Bard Peripheral Vascular, Inc. | 1 | $108 |
| Johnson & Johnson | 1 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Impel Pharmaceuticals Inc. | 4 | $66 |
| Corium, LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$36,370
- QULIPTA$25,324
- NURTEC ODT$7,789
- FARXIGA$249
- Ozempic$244
- XIFAXAN$237
- Wegovy$232
- FREESTYLE LIBRE 3$227
- VOQUEZNA$127
- Auvelity$125
- VRAYLAR$125
- Austedo XR$125
- UZEDY$125
- DEXCOM G7 GSS (161)$116
- Kerendia$114
- JARDIANCE$114
- TRELEGY ELLIPTA$113
- AIMOVIG$112
- Veozah$111
- Repatha$111
How this compares
$62,607 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 43 | $46,155 |
| Emgality PenGalcanezumab-Gnlm | 31 | $20,734 |
| QuliptaAtogepant | 19 | $19,728 |
| Nurtec OdtRimegepant Sulfate | 11 | $12,510 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,383 |
| Sumatriptan Succinate | 18 | $827 |
| Tizanidine Hcl | 16 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $47,233 | $65,88362 claims |
| PfizerNurtec Odt | $7,413 | $12,51011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Lake Charles
- Clay HillLake Charles$13K
- Alisha BernardLake Charles$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.